Top Stock Losers
Explore the biggest stock losers today along with up-to-date performance data, including the latest price, share price changes, trading volume, and more. We cover the top stock losers and decliners every day with market data, news, and analysis from our Foolish experts.
Related Articles
Featured Article
Why Altimmune Was Such a Robustly Healthy Stock on Thursday
Eric Volkman
|
Dec 19, 2024
Up More Than 500% in 2024. Can Instil Bio Keep Rocketing Higher?
Cory Renauer
|
Sep 14, 2024
A candidate that Instil Bio in-licensed this August is similar to a candidate that recently outperformed the world's top-selling cancer therapy.
Prediction: This Weight Loss Stock Will Be Acquired Within the Next Year
Adam Spatacco
|
Aug 9, 2024
Altimmune is a little-known pharmaceutical company looking to disrupt the weight loss space.
Can These 2 Biotechs Beat Eli Lilly and Novo Nordisk in Weight-Loss Drugs?
Alex Carchidi
|
Jul 20, 2024
At least one of the pair has a credible shot at finding a home in the market.
Better GLP-1 Biotech Stock: Altimmune vs. Viking Therapeutics
Alex Carchidi
|
Jul 11, 2024
Both competitors have promising lead programs, and enough cash, too.
3 Reasons Why Altimmune Stock Could Be the Next Viking Therapeutics
Alex Carchidi
|
Jun 30, 2024
While their share prices have traveled different paths recently, the similarity between the two companies is striking.
If These 3 Words Are True, Altimmune's Weight Loss Candidate Could Beat Novo Nordisk's Wegovy
Alex Carchidi
|
Jun 29, 2024
The market for weight loss medicines keeps getting hotter and hotter.
Missed Out on Eli Lilly and Novo Nordisk? This Small Biotech Has a Promising GLP-1 Drug With Significant Potential
David Jagielski
|
Apr 20, 2024
Altimmune has a modest market cap but an incredibly promising GLP-1 drug.
Forget Viking Therapeutics. Here's 1 Weight-Loss Stock to Keep Your Eyes on Instead.
Adam Spatacco
|
Apr 9, 2024
Viking Therapeutics has garnered a lot of attention following a successful clinical trial for its obesity care drug. But another development-stage biotech may have a superior candidate.
Wall Street Absolutely Loved This Biotech Stock. But It Just Crashed More Than 50%.
Keith Speights
|
Mar 22, 2023
It's not the end of the story for this once high-flying biotech stock.
View More Articles